3HOLLOMANGH J R, ZELLER S L. Overview of Poject BETA: Best practices in Evaluation and Treatment of Agitation[J]. West J Emerg Med,2012,13( 1 ) :1-2.
4STAHL S M, MORRISSETI'E D A, CITROME L, et al."Meta-guidelines" for the management of patients with schizophrenia [ J ]. CNS Spectr,2013,18 ( 3 ) : 150-162.
5MOHR P, PECENAK J, SVESTKA J, et al. Treatment of acute agitation in psychotic disorders [ J]. Neuro Endocrinol Lett,2005,26 (4) :327-335.
6ZHANG H, WANG G, ZHAO J, et al.. Intramuscular zipra- sidone versus haloperidol for managing agitation in Chinese patients with schizophrenia [ J ]. J Clin Psychopharmacol, 2013,33 (2) :178-185.
7RAIS A R, K WILLIAMS K, RAIS T, et al. Use of intra- muscular ziprasidone for the control of acute psychosis or agitation in an inpatient geriatric population: an open-label study[ J ]. Psychiatry (Edgmont) ,2010,7 ( 1 ) : 17-24.
8WILSON M P, MACDONALD K, VILKE G M, et al. Intra- muscular ziprasidone : influence of alcohol and benzodiazepines on vital signs in the emergency setting[ J ]. J Emerg Med ,2013,45 ( 6 ) :901-908.
9BALDACARA L,SANCHES M,CORDEIRO D C, et al. Ra- pid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone [ J ]. Rev Bras Psigniatr,2011,33 ( 1 ) :30-39.
10MICELI J J, TENSFELDT T G, SHIOVITZ T, et al. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single- blind, parallel-group study in patients with schizophrenia or schizoaffective disorder[ J ]. Clin Ther, 2010,32 ( 3 ) : 472 - 491.
